A crossover study is a repeated measures design in which each subject is randomly assigned to a sequence of treatments, including at least two treatments. The most damning characteristic of a crossover study is the potential of a carryover effect of one treatment to the next period. To solve the first-order crossover problem characteristic in the classic AB|BA design, the design must be extended. One alternative uses additional treatment sequences in two periods; a second option is to add a third period and repeat one of the treatments. Assuming a traditional model that specifies a first-order carryover effect, this study investigates the following alternative crossover trial designs: (1) two-treatment two-period four-sequence design (Balaam, 1968) design, (2) two treatments-three period-four sequence design (Ebbutt, 1984), and (3) three treatment-two period-six sequence design (Koch, 1983). Each design has attractive properties and, when properly applied, allows both treatment and carryover effects to be estimated.
Introduction
The most damning characteristic of a crossover study is the potential for a carryover effect of one treatment to the next period. To manage this, researchers typically include washout periods in study designs. These washout periods are thought to be of sufficient length to negate any lingering effect of one treatment into the next period. In this article, and in most of the literature on crossover designs, the persistence of a carryover effect is assumed to (1) last for only a single period (a first-order carryover effect), and (2) a carryover effect is different for different treatments. If a carryover effect is suspected in any crossover trial, then a term for this effect must be included in the model and accounted for in subsequent analysis.
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(1) a two-treatment two-period four-sequence design (Balaam, 1968) , (2) a two treatmentsthree period-four sequence design (Ebbutt, 1984) , and (3) a three treatment-two period-six sequence (Koch, 1983) design. Each design has appealing properties and -when properly applied -estimate both treatment and carryover effects.
The Traditional Crossover Design Model with Continuous Data
The traditional crossover design with ttreatments, p-periods, and s-sequences, C(t, p, s), assumes that each treatment has a simple first-order carryover effect that does not interact with the direct effect of the treatment in the subsequent period, and that subject effects are either fixed or random. Though a variety of models are considered in the literature, virtually all work in crossover designs uses the same underlying statistical model. This model assumes the following for the response of patient y ij : If y ij denotes the observed response of subject j (j = 1, …, n) in period i (i = 1, …, p), then
Where π i is the effect of period i, τ d(i,j) is the direct effect of treatment D, λ d(i-1,j) is the simple first-order carryover effect of treatment D, d(i, j) is the treatment allocated to patient j in period i, and λ d(0,j) = 0 for all j. It is assumed that all effects are fixed effects. β j is the effect of patient j and ε ij is the error term. The random subject effect, β j , and the experimental error, ε ij , are assumed to be mutually independently distributed as N (0, σ 2 β ) and N (0, σ 2 ε ). The primary purpose of a crossover design comparing treatments A and B is to estimate the treatment contrast τ A -τ B . The period effects (π 1 and π 2 ), the first order carryover effects (λ A and λ B ) and μ are typically regarded as nuisance parameters that are desirable to eliminate from any estimate. To solve the first-order crossover problem in the two-treatment two-period crossover design, one possible solution is to extend the design to four sequences. Balaam's C(2, 2, 4) design (Balaam, 1968) , AA|AB|BA|BB, is generally accepted as optimal for estimating treatment effects and is also more efficient than the classic C(2, 2, 2) design (Laska, Meisner & Kushner, 1983) . If the carryover effect is absent, this design is inefficient because many subjects likely will not contribute any information to the estimate of treatment differences in the two sequences AA and BB. Using Balaam's design, unbiased estimates of the treatment differences and carryover effects are easily derived (see Table  1 ).
The second design strategy is to extend the classic design by adding a third period and repeating one of the two treatments. The treatment sequences will ensure that the first two trial periods constitute a conventional twoperiod crossover trial if the third treatment period leads to excessive subject drop-outs. Ebbutt's efficient C(2, 3, 4) design, the ABB| BAA|ABA|BAB (Ebbutt, 1984) illustrates this second strategy. This design, with equal number of subjects per sequence, is able to estimate all parameters in the traditional model and provide an unbiased estimate of the treatment contrast (Ebbutt, 1984; Heydat & Stufken, 2003; Liang & Carriere, 2010 ) (see Table 2 Koch's crossover design comparing two treatments A and B to a placebo P, uses six sequences AB, BA, AP, BP, PA, and PB (see Table 3 ). These six sequences enable the estimation of period effects, treatment effects and carryover effects from within-subject information. The four hypotheses of interest are: Koch's C(3, 2, 6) design has six sequences, AB, BA, AC, CA, BC and CB (see Table 4 ). In this design, the hypotheses of interest are: 
Conclusion
Optimal crossover designs are statistically efficient and require fewer subjects for the same number of observations than do non-crossover designs. Because variability is typically less within a subject than between different subjects, there is a corresponding increase in the precision of observations. The result: fewer subjects are required to detect a treatment difference. For example, if N parallel is the total number of subjects required for a two-way parallel trial to detect a treatment effect (δ) with 5% significance and 80% power, the total number of subjects N crossover required for a 2 x 2 crossover trial to detect the same effect is approximately N crossover = (1 − r)N parallel /2, where r is a correlation coefficient among the repeated measurements of the primary endpoint. The major concern -and subject of countless discussions -in a crossover study is the presence of a carryover effect. The standard way to avoid the carryover effect is to include a rest period between successive periods, hoping that the carryover effect will wash out. The inclusion of a rest period between each pair of successive periods increases the total duration of the experiment and there is no guarantee that any carryover effect will be eliminated.
To address the potential of first-order carryover effects, the classic AB|BA crossover design could easily be extended to one of the designs outlined herein. In effect, either the added sequence(s) or added treatment period permits direct estimates of treatment effect and examination of any carryover effects. 
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